Quantinno Capital Management LP Has $469,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

Quantinno Capital Management LP increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 32.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,308 shares of the biotechnology company’s stock after buying an additional 322 shares during the quarter. Quantinno Capital Management LP’s holdings in United Therapeutics were worth $469,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Tri Locum Partners LP acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $15,959,000. Bridgewater Associates LP grew its position in United Therapeutics by 384.3% in the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock valued at $22,130,000 after purchasing an additional 49,003 shares in the last quarter. Renaissance Technologies LLC increased its stake in United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after buying an additional 22,978 shares during the last quarter. Vontobel Holding Ltd. lifted its position in United Therapeutics by 90.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 1,664 shares of the biotechnology company’s stock worth $596,000 after buying an additional 790 shares in the last quarter. Finally, Glenmede Trust Co. NA boosted its stake in shares of United Therapeutics by 6.4% during the 3rd quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock worth $24,585,000 after buying an additional 4,145 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other news, Director Christopher Causey sold 510 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 119,340 shares of company stock valued at $44,765,530 over the last 90 days. 11.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

UTHR has been the topic of several analyst reports. HC Wainwright upped their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group increased their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. TD Cowen raised their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Argus upped their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $361.81 on Friday. The firm has a market cap of $16.15 billion, a price-to-earnings ratio of 15.89, a P/E/G ratio of 1.05 and a beta of 0.54. The stock’s fifty day moving average price is $369.94 and its two-hundred day moving average price is $342.19. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period last year, the firm earned $5.38 earnings per share. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.